コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 erimentally infected mice and a patient with pulmonary cryptococcosis.
2 e investigated the expression of iNOS in rat pulmonary cryptococcosis.
3 ntifungal therapy versus 27.7% with isolated pulmonary cryptococcosis.
4 with exacerbated disease in murine models of pulmonary cryptococcosis.
5 d macrophage function using a mouse model of pulmonary cryptococcosis.
6 amics have been reported in the rat model of pulmonary cryptococcosis.
7 IFN-gamma responsiveness during experimental pulmonary cryptococcosis.
8 ary nodules in immunocompetent patients with pulmonary cryptococcosis.
9 ages are an important source of MCP-1 during pulmonary cryptococcosis and that MCP-1 production is ac
10 treatment approaches for non-meningeal, non-pulmonary cryptococcosis are based on those used for cry
11 and suggest a potential role for subclinical pulmonary cryptococcosis in the pathogenesis of asthma.
14 GM-CSF) in host defense in a murine model of pulmonary cryptococcosis induced by intratracheal inocul
15 t although both BALB/c and C.B-17 mice clear pulmonary cryptococcosis through T cell-mediated mechani
16 g a rat model, we explored the potential for pulmonary cryptococcosis to modify allergic responses an
21 unocompetent patients with clinically proved pulmonary cryptococcosis were retrospectively reviewed b
22 inant of AmB-tolerant persister formation in pulmonary cryptococcosis, which has potential clinical s
23 We present a rare case of non-meningeal, non-pulmonary cryptococcosis with clinical manifestations li